

4th December 2019 | CannPal Animal Therapeutics Limited ACN: 612 791 518 |
ASX:CP1

CannPal Removed from the Restricted List of BNY's Global Cannabis Securities Policy

4th December 2019: Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to advise that it has been removed from the restricted list of BNY Mellon's Global Cannabis Securities Policy.

This follows the news that major American financial institution, Bank of New York Mellon, announced its new restrictive policy on cannabis stocks and would not be accepting positions with certain marijuana-related businesses.

Local BNY Mellon-owned clearing house, Pershing, also restricted trading for a number of Australian listed cannabis stocks, with CannPal being named as one of the Companies on the restricted list.

CannPal operates in complete compliance across State and Federal laws in both Australia and the United States, and are pleased to advise that after review, the Company has been added to the permitted to trade list from the 30th of November 2019.

About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals. To learn more please visit: www.cannpal.com

ENDS

For further information, please contact:

CannPal

Layton Mills
Founder and Managing Director
M: +61 431 302 667
E: layton@cannpal.com

